Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of dosing time on sunitinib pharmacokinetics
NL-OMON39190Recruiting
- Sponsor
- Erasmus MC
- Start
- Jul 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of sunitinib in renal cell carcinoma (RCC), gastrointestinal stromal tumor (GIST) and islet cell tumor, sponsored by Erasmus MC. Started Jul 2012; status: recruiting.
02
Drugs
sunitinib
03
Conditions
renal cell carcinoma (RCC)gastrointestinal stromal tumor (GIST)islet cell tumor
Beyond the preview
Go deeper on NL-OMON39190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39190.